Development of peptidic MERS-CoV entry inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1513-1519, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-320049
ABSTRACT
In 2012, a new SARS-like coronavirus emerged in the Middle East, namely the Middle East respiratory syndrome coronavirus (MERS-CoV). It has caused outbreaks with high mortality. During infection of target cell, MERS-CoV S protein S1 subunit binds to the cellular receptor (DPP4), and its S2 subunit HR1 and HR2 regions intact with each other to form a stable six-helix bundle to mediate the fusion between virus and target cell membranes. Hence, blocking the process of six-helix bundle formation can effectively inhibit MERS-CoV entry into the target cells. This review focuses on the recent advance in the development of peptidic entry inhibitors targeting the MERS-CoV S2 subunit.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Peptides
/
Pharmacology
/
Physiology
/
Drug Design
/
Coronavirus Infections
/
Dipeptidyl Peptidase 4
/
Drug Therapy
/
Virus Internalization
/
Spike Glycoprotein, Coronavirus
Limits:
Humans
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS